ERBBal Remedies: Combination Therapy for EGFR-mutant Lung Cancers

Pang-Dian Fan; Helena A Yu

doi:10.1158/1078-0432.CCR-18-2179

ERBBal Remedies: Combination Therapy for EGFR-mutant Lung Cancers

Clin Cancer Res. 2018 Nov 15;24(22):5499-5501. doi: 10.1158/1078-0432.CCR-18-2179. Epub 2018 Aug 22.

Authors

Pang-Dian Fan¹, Helena A Yu^{2

3}

Affiliations

¹ Department of Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
² Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. yuh@mskcc.org.
³ Weill Cornell Medical College, New York, New York.

PMID: 30135146
DOI: 10.1158/1078-0432.CCR-18-2179

Abstract

Multiple members of the ERBB/HER family of the receptor tyrosine kinases have been implicated in mediating acquired resistance to EGFR inhibitors that are used to treat EGFR-mutant lung cancers. New single agents and combination therapies targeting the ERBB/HER family members are being investigated to either prevent or overcome the emergence of acquired resistance. Clin Cancer Res; 24(22); 5499-501. ©2018 AACR See related article by Romaniello et al., p. 5610.

Publication types

Comment

MeSH terms

Acrylamides
Aniline Compounds
Drug Resistance, Neoplasm / drug effects
ErbB Receptors*
Female
Humans
Lung Neoplasms*
Protein Kinase Inhibitors

Substances

Acrylamides
Aniline Compounds
Protein Kinase Inhibitors
osimertinib
EGFR protein, human
ErbB Receptors